Gilead Sciences GILD
NASDAQ GILD
$145.69 -0.95 (-0.65%)
As of: Sep 9, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Construction in Progress (2010 - 2025)

Gilead Sciences' (GILD) quarterly Construction in Progress came in at $745.0 million in Q4 2025, up 48.7% on a YoY basis from $501.0 million in Q4 2024, and up 48.7% quarter-over-quarter from $501.0 million in Q4 2024.

Analysis

Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends

Gilead Sciences (GILD) has reported Construction in Progress for 16 consecutive years, with $745.0 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Construction in Progress rose 48.7% year-over-year to $745.0 million; the trailing twelve-month figure through Dec 2025 stood at $745.0 million (up 48.7% YoY), and the FY2025 full-year result was $745.0 million, up 48.7% from the prior year.
  • Construction in Progress improved to $745.0 million in Q4 2025 per GILD's latest filing, from $501.0 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $1.1 billion in Q4 2021 and bottomed at $501.0 million in Q4 2024.
  • Historically, Construction in Progress has averaged $736.6 million across 5 years, with a median of $719.0 million in 2022.
  • The sharpest annual moves came in 2022 and 2025: Construction in Progress plunged 31.98% in 2022, then surged 48.7% in 2025.
  • Over 5 years, Construction in Progress stood at $1.1 billion in 2021, then slumped by 31.98% to $719.0 million in 2022, then slipped by 8.07% to $661.0 million in 2023, then slipped by 24.21% to $501.0 million in 2024, then soared by 48.7% to $745.0 million in 2025.
  • According to Business Quant data, Construction in Progress over the past three periods registered $745.0 million, $501.0 million, and $661.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn -
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn -
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn -
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 745.00 Mn
Dec 31, 2024 501.00 Mn
Dec 31, 2023 661.00 Mn
Dec 31, 2022 719.00 Mn
Dec 31, 2021 1.06 Bn
Dec 31, 2020 856.00 Mn
Dec 31, 2019 723.00 Mn
Dec 31, 2018 1.19 Bn
Dec 31, 2017 690.00 Mn
Dec 31, 2016 641.00 Mn
Dec 31, 2015 554.00 Mn
Dec 31, 2014 411.00 Mn
Dec 31, 2013 129.00 Mn
Dec 31, 2012 216.43 Mn
Dec 31, 2011 60.75 Mn
Dec 31, 2010 82.33 Mn